News Posts List
With $275M in New NIH Funding, TCGA to Study Kidney Cancer
10/01/2009
Among more than 20 cancer types "likely to be considered" a high priority for TCGA are clear cell renal cell carcinoma and invasive ductal carcinoma of the breast.
Marks Prize Recognizes Young Cancer Researchers
09/30/2009
Dr. Sabatini discovered mTOR when he was studying the small molecule rapamycin, a compound that was known to have immunosuppressive and anticancer properties. (mTOR stands for mammalian target of rapamycin.) Two derivatives of rapamycin, temsirolimus (Torisel®) and everolimus (Afinitor®), both of which target the mTOR pathway, are now approved for the treatment of kidney cancer.
Kidney Cancer Association Symposium Highlights
09/29/2009
The medical press covers the 8th International Kidney Cancer Symposium, in Chicago, sponsored by the Kidney Cancer Association. This web page features 12 articles from the September, 2009, meeting.
Updated Single Agent Phase 2 Data of KRX-0401
09/29/2009
Keryx Biopharmaceuticals, Inc. today announced updated clinical results from a Phase 2 study of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single-agent treatment for advanced metastatic renal cell carcinoma (RCC). Dr. Thomas E. Hutson, Director of the Genitourinary Oncology Program at Baylor-Sammons Cancer Center in Dallas, Texas, presented the data on Saturday, September 26th, in an oral presentation featured at the Eighth International Kidney Cancer Symposium held in Chicago.
Results from a Phase II trial of regorafenib (BAY 73-4506),
09/22/2009
Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC). These data were presented in an oral session at the joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology (ECCO 15 - 34th ESMO).
Kidney Cancer Research: Medical Center awarded $11.5 million
09/16/2009
The National Cancer Institute (NCI) has awarded Beth Israel Deaconess Medical Center (BIDMC) an $11.5 million, five-year SPORE grant to focus on cancers of the kidney. Michael Atkins, MD, Deputy Director of BIDMC's Division of Hematology/Oncology, will oversee the grant, which involves collaborations with Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital via the Dana-Farber/Harvard Cancer Center.
Video: 'Kidney Cancer: Jane's Journey'
09/14/2009
Hall of Famer Sutton high on 'brother' Jake
09/09/2009
The 64-year-old Atlanta Braves radio announcer certainly knows something about winning. His on-field success earned him his induction to the Hall of Fame in 1998, but it was his successful battle against kidney cancer that has defined his post-baseball career.
News Feed